(Q38026784)

27 August 2017

title

B-cell depletion in the treatment of lupus nephritis (English)

1 reference

27 August 2017

Jon W Gregersen

1

1 reference

27 August 2017

David R W Jayne

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

17 July 2012

1 reference

Nature Reviews Nephrology

27 August 2017

published in

1 reference

27 August 2017

volume

8

1 reference

27 August 2017

issue

9

1 reference

27 August 2017

page(s)

505-514

1 reference

Systemic lupus erythematosus.

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Pathogenesis of kidney disease in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

The classification of glomerulonephritis in systemic lupus erythematosus revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Treatment of proliferative lupus nephritis: a slowly changing landscape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

B cells in glomerulonephritis: focus on lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

B cell biomarkers of rituximab responses in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Updates on the treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Treatment of systemic lupus erythematosus with epratuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

BAFF: a local and systemic target in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Lifetime trajectory of physical activity according to energy expenditure and joint force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

The long-term outcome of 93 patients with proliferative lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Rituximab-treated membranous lupus nephritis: clinical outcome and effects on electron dense deposits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Thrombovascular events in systemic lupus erythematosus: comment on the article by Jung et al.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.141

Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.

31 March 2020

1 reference

12 December 2020

Renal biopsy in lupus patients with low levels of proteinuria.

1 reference

12 December 2020

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.

1 reference

12 December 2020

Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95.

1 reference

12 December 2020

Lupus nephritis: an historical perspective 1968-1998.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2012.141

1 reference

27 August 2017

1 reference